Dave Farrow

Dave Farrow is Director – Scientific Affairs at Aptar Pharma. He began his career as an Inhalation Scientist at Sanofi Aventis, working on exploratory development products through to commercial marketed products and the whole lifecycle in between. He then held a similar role at Novartis where he further developed his inhalation knowledge. Following this, Mr Farrow moved to Vectura as Particle Engineering Specialist, going on to become Principal Scientist, then manager of the Bioformulation and Particle Engineering group. At Charles River, he led and developed the team conducting safety assessment/toxicology studies with aerosols. Mr Farrow then moved to Albany Molecular Research Inc. (now Curia), leading the R&D groups and conducting business development activities before joining Nanopharm, starting as Director of Operations, then became Chief Operations Officer. Mr Farrow moved to Nanopharm’s parent company, Aptar Pharma, and was appointed Director of Science and Technology for the Aptar Pharma Prescription division in February 2024 and Director of Scientific Affairs for Aptar Pharma in 2025.